CareDxSTU:1K9 -3.13%74 FCF Margin % is 0.44% as of Mar. 2026. GuruFocus rates STU:1K9 with a GF Score™ of 74/100 and a GF Value™ of €18.45 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, CareDx ranks better than 84.24% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CareDx's Free Cash Flow for the
three
months ended in Mar. 2026 was €0.4 Mil. CareDx's Revenue for the
three
months ended in Mar. 2026 was €101.8 Mil. Therefore, CareDx's FCF Margin % for the quarter that ended in Mar. 2026 was 0.44%.
The historical rank and industry rank for CareDx's FCF Margin % or its related term are showing as below:
STU:1K9'
s FCF Margin % Range Over the Past 10 Years
Min: -42.02 Med: -11.6 Max: 15.46
Current: 15.46
During the past 13 years, the highest FCF Margin % of CareDx was 15.46%. The lowest was -42.02%. And the median was -11.60%.
STU:1K9's FCF Margin % is ranked better than 84.24% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.89
vs STU:1K9: 15.46
CareDx FCF Margin % Related Terms
CareDx FCF Margin % Historical Data
* Premium members only.
The historical data trend for CareDx's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1K9 vs PSNL, OPK, NEO: FCF Margin % Comparison
For the Diagnostics & Research subindustry, CareDx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareDx FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's FCF Margin % distribution charts can be found below:
* The bar in red indicates where CareDx's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CareDx (STU:1K9) has a FCF Margin % of 0.44% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CareDx and its competitors. According to the industry distribution chart, CareDx ranks #32 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 15.8%.
Is CareDx's FCF Margin % too high?
CareDx's current FCF Margin % is 0.44%. Based on the distribution chart, CareDx ranks #32 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, CareDx has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CareDx's FCF Margin % compare to PSNL and OPK?
According to the Medical Diagnostics & Research industry distribution chart, CareDx ranks #32 out of 203 companies for FCF Margin %. This places CareDx in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CareDx and its competitors. CareDx's current FCF Margin % is 0.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareDx stock overvalued right now?
Based on GuruFocus' analysis, CareDx (STU:1K9) is currently considered Significantly Overvalued. The stock's GF Value™ is €18.45, compared to a current price of €25.60 — trading 38.8% above its estimated fair value. The current FCF Margin % is 0.44%. CareDx's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For CareDx (STU:1K9), the current FCF Margin % is 0.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareDx (STU:1K9) Overvalued in 2026?
Based on GuruFocus' analysis, CareDx stock appears to be overvalued.
The current stock price of €25.60 is trading 38.8% above its estimated GF Value™ of €18.45.
GuruFocus considers CareDx to be Significantly Overvalued.
Key valuation signals for STU:1K9:
FCF Margin %: 0.44%
GF Value™: €18.45 vs. price of €25.60 (38.8% above fair value)
No single metric tells the full story. See the STU:1K9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
74GF Score
Get the complete analysis for STU:1K9
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1K9 has been successfully added to your 
